Scilex Holding Company (NASDAQ:SCLX - Get Free Report)'s stock price was up 3.7% during mid-day trading on Thursday . The stock traded as high as $14.77 and last traded at $13.42. Approximately 187,049 shares traded hands during trading, a decline of 18% from the average daily volume of 229,039 shares. The stock had previously closed at $12.94.
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on SCLX shares. D Boral Capital lowered Scilex from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 11th. D. Boral Capital reaffirmed a "hold" rating on shares of Scilex in a research report on Friday, April 11th.
Get Our Latest Stock Analysis on SCLX
Scilex Trading Down 6.6%
The company has a 50-day moving average price of $7.36 and a two-hundred day moving average price of $8.53. The stock has a market capitalization of $97.15 million, a P/E ratio of -0.48 and a beta of 1.31.
Institutional Trading of Scilex
Large investors have recently made changes to their positions in the company. Norges Bank acquired a new position in Scilex during the 4th quarter valued at about $204,000. Northern Trust Corp boosted its stake in Scilex by 64.0% during the 4th quarter. Northern Trust Corp now owns 1,273,968 shares of the company's stock valued at $543,000 after purchasing an additional 497,182 shares during the last quarter. Jane Street Group LLC boosted its stake in Scilex by 965.8% during the 4th quarter. Jane Street Group LLC now owns 321,480 shares of the company's stock valued at $137,000 after purchasing an additional 291,316 shares during the last quarter. RA Capital Management L.P. boosted its stake in Scilex by 296.7% during the 4th quarter. RA Capital Management L.P. now owns 1,036,218 shares of the company's stock valued at $442,000 after purchasing an additional 775,039 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in Scilex by 28.7% during the 4th quarter. Janus Henderson Group PLC now owns 687,547 shares of the company's stock valued at $293,000 after purchasing an additional 153,245 shares during the last quarter. 69.67% of the stock is currently owned by institutional investors and hedge funds.
About Scilex
(
Get Free Report)
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Featured Articles
Before you consider Scilex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scilex wasn't on the list.
While Scilex currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access